Over the recent years, an extensive array of bioglass benefits including good osteostimulativity, osteoconductivity, mechanical strength, and degradability have been instrumental in unlocking critical growth opportunities for bioglass fiber market players across the orthopedics application. Upon implantation into the body, these products effectively reinforce the bonding between hard and soft tissues, promote the formation of dense HA (hydroxyapatite) layer on the surface, and rapidly combine with bone tissue for inducing and accelerating the process of bone growth.
These properties of bioactive glass have propelled an increase in studies pertaining to BG application in numerous orthopedic areas comprising BG bone cement, BG nanoparticles, BG coating, BG nanofibers, drug and biological factor-load BG, BG scaffolds, injectable BG-based hydrogels/pastes, metal ion-loaded BG, and others. Similar initiatives are expected to augment bioglass fiber market size, which is anticipated to surpass USD 15.3 million by 2027, according to Global Market Insights Inc.
Rising demand for borate-based glass and glass ceramic products
While the market revenue from borate-based glass is estimated to exhibit a CAGR of 9% through the estimated period, the glass ceramic segment is expected to account for an appreciable valuation through 2027.
This growth can be attributed to the mounting adoption of glass ceramics in dental care products including corrosion inhibitors and filler materials. Optimum bone-grafting ability and good biocompatibility are additional factors expected to push product demand over the coming years.
Growing research activities pertaining to dental application
Numerous organizations are taking a keen interest in conducting research initiatives centered on the applicability of bioglass fiber in the field of dental care. One such study, published in May 2021, aimed at investigating the bioactivity and cytotoxicity of a novel nanocomposite containing nBGs (nanoparticles of bioactive glass) on human dental pulp stem cells (hDPSCs).
The research found that the use of nBG/BD not only enabled hDPSC proliferation and attachment but also escalated the expression of ALP in mineral-producing cells. The findings are slated to create opportunities for the deployment of nBG/BD in vital pulp therapies.
Europe bioglass fiber market: Increasing number of product approvals to drive business landscape in the region
The European region has recorded an upsurge in the approval of newly developed products by regulatory bodies across various countries. For instance, in May 2021, Prosidyan, Inc., secured two CE Marks for its FIBERGRAFT BG Morsels, FIBERGRAFT BG Putty GPS, and FIBERGRAFT BG Putty. Made from proprietary micro- and nano-sized bioactive glass fibers, the FIBERGRAFT substitute provides numerous advantages such as optimized rates of resorption, high surface area, and direct connectivity.
Steps taken by leading industry players: A brief overview
Major companies in the bioglass fiber industry comprise Mo-Sci Corporation (The Heraeus Group), Vetra Biomaterials, Corbion Biotech, Inc., Prosidyan, Inc., ETS Wound Care LLC., and others. These participants are depicting a greater inclination towards the implementation of strategic initiatives including collaborative agreements, mergers, and acquisitions for consolidating their position in the market.
For instance, in September 2021, The Heraeus Group acquired ETS Technology Holdings LLC and Mo-Sci Corporation. The move strengthened the group’s healthcare and medical technology portfolio, which comprises market leadership in the supply of medical devices and components.
In a nutshell, the increasing product adoption across healthcare systems in developed countries, owing to multiple benefits such as voluntary funding, government schemes, and attractive medical insurances, is expected to bolster bioglass fiber market share through the forthcoming years.